Nektar Therapeutics (NASDAQ:NKTR) will present Phase 2b clinical data for rezpegaldesleukin at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, the company announced.
The data, which will be delivered in two separate oral presentations on March 28, marks a significant milestone for the San Francisco-based biopharmaceutical firm as it advances its lead immunology asset through mid-stage testing.
The scheduled presentations will provide a comprehensive look at the 36-week efficacy and safety of rezpegaldesleukin, a first-in-class T-regulatory (Treg) cell stimulator.
One session will focus on the treatment of severe-to-very-severe alopecia areata, an autoimmune condition characterized by hair loss, while the second will detail severity-dependent results in patients suffering from moderate-to-severe atopic dermatitis.
Rezpegaldesleukin, developed in a strategic pivot toward immunology, aims to selectively expand Treg cells to restore immune balance.
The 36-week results are expected to offer insight into the durability of the drug's effect and its safety profile compared to existing therapies.
The AAD meeting, running from March 27 to March 31, serves as a primary venue for dermatological clinical breakthroughs, and the selection for oral presentation underscores the industry's interest in Nektar’s Treg-based approach.
Investors have closely watched Nektar’s clinical progress since the company regained full rights to the program following its previous collaboration with Eli Lilly.
With a cash runway currently projected through 2026, the upcoming data readout in Denver is viewed as a critical catalyst for the company’s valuation and its ability to potentially move rezpegaldesleukin into pivotal Phase 3 trials.